

# Central Nervous System Oxygen Toxicity and Hyperbaric Oxygen Seizures

Edward P. Manning

- INTRODUCTION:** The use of hyperbaric oxygen ( $O_2$ ) as a therapeutic agent carries with it the risk of central nervous system (CNS)  $O_2$  toxicity.
- METHODS:** To further the understanding of this risk and the nature of its molecular mechanism, a review was conducted on the literature from various fields.
- RESULTS:** Numerous physiological changes are produced by increased partial pressures of oxygen ( $PO_2$ ), which may ultimately result in CNS  $O_2$  toxicity. The human body has several equilibrated safeguards that minimize effects of reactive species on neural networks, believed to play a primary role in CNS  $O_2$  toxicity. Increased partial pressure of oxygen ( $PO_2$ ) appears to saturate protective enzymes and unfavorably shift protective reactions in the direction of neural network overstimulation. Certain regions of the CNS appear more susceptible than others to these effects. Failure to decrease the elevated  $PO_2$  can result in a tonic-clonic seizure and death. Randomized, controlled studies in human populations would require a multicenter trial over a long period of time with numerous endpoints used to identify  $O_2$  toxicity.
- CONCLUSIONS:** The mounting scientific evidence and apparent increase in the number of hyperbaric  $O_2$  treatments demonstrate a need for further study in the near future.
- KEYWORDS:** hyperbaric oxygen seizures, hyperbaric oxygen therapy, CNS oxygen toxicity.

Manning EP. Central nervous system oxygen toxicity and hyperbaric oxygen seizures. *Aerosp Med Hum Perform*. 2016; 87(5):477–486.

Modern therapeutic use of hyperbaric oxygen ( $HBO_2$ ) in clinical medicine began in the 1950s.<sup>64,83</sup> Boerema, a Dutch surgeon, in conjunction with the Royal Dutch Navy, was the first physician to “drench” the tissue of a patient with increased partial pressure of oxygen ( $PO_2$ ) with the use of a hyperbaric chamber.<sup>16</sup> Through his work and subsequent experiments,  $HBO_2$  has been shown to have positive effects in treating wounds,<sup>67,104</sup> and as a treatment for carbon monoxide (CO) toxicity.<sup>85,89</sup> In 1977, Blue Cross/Blue Shield accepted a report from the Undersea Medical Society (now Undersea and Hyperbaric Medical Society) on hyperbaric oxygenation, which resulted in a list of disorders for which hyperbaric treatment should be considered. Many of today’s indications for hyperbaric oxygen therapy ( $HBO_2T$ ) stem from this list. Current indications for  $HBO_2T$  covered by Medicare are shown in to **Table I**.<sup>79,84,94</sup> More research is needed to conclude for which indications  $HBO_2T$  is most beneficial and to what extent.<sup>32</sup>

$HBO_2T$  is a therapeutic modality that exposes the body to 100% inspired oxygen ( $O_2$ ) at ambient pressures greater than one atmosphere.<sup>79,107</sup> Therapeutic administration of

supplemental  $O_2$  generally refers to increasing the fractional inspired  $O_2$  ( $F_{IO_2}$ ). Without the use of a hyperbaric chamber,  $F_{IO_2}$  equals the partial pressure of inspired  $O_2$  ( $P_{IO_2}$ ). This limits the range of  $P_{IO_2}$  from 0.21 ATA [ $F_{IO_2} = 21\%$  at one atmosphere of absolute pressure (ATA)] to 1.0 ATA ( $F_{IO_2} = 100\%$  at 1 ATA); 1 ATA equals one atmosphere of pressure at sea level. Hyperbaric chambers increase ambient pressure, allowing the  $P_{IO_2}$  to exceed 1 ATA. The majority of clinical uses for  $HBO_2T$  derive their benefit from the increased  $PO_2$  that  $HBO_2T$  provides.<sup>17</sup> The increased  $PO_2$  delivered throughout the body causes reactive oxidative species (ROS) that promote wound healing and postischemic tissue survival.<sup>105</sup> Hydrostatic effects of  $HBO_2T$  that affect bubble size are beneficial for illnesses

From the Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA.

This manuscript was received for review in August 2015. It was accepted for publication in January 2016.

Address correspondence to: Edward P. Manning, M.D., Ph.D., Department of Medicine, Hospital of the University of Pennsylvania, 100 Centrex, 3400 Spruce St., Philadelphia, PA 19104; edward.manning@uphs.upenn.edu.

Reprint & Copyright © by the Aerospace Medical Association, Alexandria, VA.

DOI: 10.3357/AMHP.4463.2016

**Table I.** Examples of Therapeutic Uses of HBO<sub>2</sub>.

ELECTIVE INDICATIONS	EMERGENT INDICATIONS
Radiation injury*	Carbon monoxide poisoning
Compromised skin grafts	Decompression illness
Chronic nonhealing wounds <sup>#</sup>	Gas gangrene
Refractory osteomyelitis	Arterial gas embolism
Inhibition of clostridium perfringens	Ischemia-reperfusion injury
Suppression of autoimmune responses	Hemorrhagic anemia
Tissue salvage in burn victims	
Nerve cell regeneration	
Preparation and preservation of skin grafts	

\*"Radiation injury" includes soft tissue radionecrosis, osteoradionecrosis, and hemorrhagic radiation cystitis.

<sup>#</sup> Particularly diabetic ulcers

such as decompression sickness.<sup>83</sup> HBO<sub>2</sub>T has been gaining increased attention in the popular press<sup>87,113</sup> and among scientific researchers.<sup>70</sup>

The toxic nature of O<sub>2</sub> is often underappreciated. There are side effects of the hydrostatic and oxidative changes that HBO<sub>2</sub>T creates, including HBO<sub>2</sub> seizures.<sup>18,92</sup> Determining mechanisms of HBO<sub>2</sub> toxicity and its ability to cause seizures has been an effort of researchers in the hopes of maximizing the potential benefits of HBO<sub>2</sub>T while minimizing its risks.

Both patients and hyperbaric medical attendants are routinely exposed to the hyperbaric environment (although attendants do not routinely breathe HBO<sub>2</sub>) and are therefore exposed to an increased risk of O<sub>2</sub> toxicity. There are special populations outside of medicine who are also routinely exposed to HBO<sub>2</sub>, including military, commercial and recreational divers, and subterranean workers.<sup>37,49,118</sup> The risk of O<sub>2</sub> toxicity is increased when the ratio of O<sub>2</sub> to inert gas is raised in the hopes of minimizing deleterious gas effects. Combat divers use pure O<sub>2</sub> via a rebreather apparatus for clandestine purposes (to avoid bubbles).<sup>37,82</sup> High PO<sub>2</sub> greatly increases the risk of O<sub>2</sub> toxicity even at shallow depths but it also purges nitrogen from a diver's body. Following missions, divers can be extracted and flown well above sea level with little concern for decompression sickness, making it ideal for clandestine and lengthy underwater operations.<sup>43,82</sup> Concerns over CNS O<sub>2</sub> toxicity remain a limiting factor in standard operating procedures for closed-circuit diving operations and HBO<sub>2</sub>T alike.<sup>37,83</sup> Some deleterious effects of gases under pressure and the populations at risk are listed in **Table II**.

O<sub>2</sub> toxicity in humans can be categorized into two major types: low pressure or chronic O<sub>2</sub> toxicity, such as pulmonary

toxicity, nonspecific cellular toxicity, organ damage and erythrocyte hemolysis; and high pressure or acute O<sub>2</sub> toxicity, most commonly associated with CNS O<sub>2</sub> toxicity.<sup>29,106</sup> Chronic toxicity tends to occur when the PO<sub>2</sub> exceeds 0.5 ATA for extended periods of time. People may be most familiar with retinal manifestations of O<sub>2</sub> toxicity resulting in blindness of premature neonates. Prolonged exposure to elevated PO<sub>2</sub>, whether increased concentrations of oxygen inspired at atmospheric pressure or low concentrations of inspired oxygen at high ambient pressures, places humans at risk for pulmonary oxygen toxicity.<sup>44,45</sup> It is characterized by decrease in pulmonary function, chest tightness, exertional dyspnea, and cough. Moderate to severe cases can involve pulmonary edema, hemorrhage, or death.<sup>42,44</sup>

The risk of CNS O<sub>2</sub> toxicity is a function of both PO<sub>2</sub> and exposure time, directly proportional to both: the greater the PO<sub>2</sub>, the greater the risk of HBO<sub>2</sub> seizure.<sup>61</sup> While the onset of seizures is usually in the vicinity of 2–3 ATA, the pressure at onset may be significantly lowered by coexisting conditions such as immersion, exercise, and respiratory acidosis due to moderate CO<sub>2</sub> retention.<sup>69</sup> 1.9 ATA is a noticeable threshold for increased risk.<sup>69,77</sup> Even at lower PO<sub>2</sub> HBO<sub>2</sub> seizures can occur particularly when combined with inert gases or carbon monoxide (CO).<sup>9,52</sup> The most dramatic manifestation of CNS O<sub>2</sub> toxicity is an HBO<sub>2</sub>-induced seizure. Additional effects of CNS O<sub>2</sub> toxicity may also occur, including autonomic, motor, and cardiorespiratory signs and symptoms,<sup>40</sup> such as bradycardia, hyperventilation, dyspnea, and altered cardiorespiratory neural reflexes.<sup>43</sup>

CNS O<sub>2</sub> toxicity often presents acutely with little or no warning. Common signs and symptoms of CNS O<sub>2</sub> toxicity are easily remembered using the mnemonic VENTID-C<sup>3,11,83</sup>:

Visual symptoms: tunnel vision, blurred vision, or decreased peripheral vision  
 Ear symptoms: tinnitus, roaring, pulsing sounds, or perceived sounds not from an external stimulus  
 Nausea: often with vomiting and headache  
 Twitching/Tingling: of extremities, facial muscles  
 Irritability: or any change in mental status such as confusion, agitation, anxiety, or undue fatigue  
 Dizziness: or clumsiness, loss of coordination  
 Convulsions: and death

Unfortunately many of these symptoms are not exclusive to O<sub>2</sub> toxicity, and CNS O<sub>2</sub> toxicity does not usually proceed through any predictable sequence of the above signs. Convulsions,

**Table II.** Physiological Effects of Gases Under Pressure.\*

DEPTH (PRESSURE) OF ONSET	POPULATION	TOXICITY	SOURCE
Sea level (1 ATA)	Everyone	CO	Incomplete hydrocarbon combustion
		O <sub>2</sub> (pulmonary, retinal)	Long exposures to 100% O <sub>2</sub>
		CO <sub>2</sub>	Inadequate ventilation
12 fsw (1.3 ATA)	Closed-circuit diver	O <sub>2</sub> (CNS)	Breathing 100% O <sub>2</sub>
45 fsw (2.4 ATA)	HBO <sub>2</sub> T	O <sub>2</sub> (CNS)	Breathing 100% O <sub>2</sub>
99 fsw (4 ATA)	Open-circuit diver	N <sub>2</sub>	Breathing compressed air
165 fsw (6 ATA)	Open-circuit diver	O <sub>2</sub> (CNS)	Breathing compressed air

fsw = feet of sea water.

\*This list does not include decompression sickness (DCS), which may occur at virtually any depth given the proper circumstances.

the most serious effect of O<sub>2</sub> toxicity due to its fatal potential if left untreated, may occur without warning or other accompanying signs.<sup>43,64</sup> O<sub>2</sub>-induced seizures are characterized as generalized tonic-clonic seizures, though focal seizures may be the only neurological manifestation at times.<sup>64,99</sup> During the seizure, the individual loses consciousness and convulses, usually progressing through both a tonic phase, in which all of the muscles are stimulated at once and lock the body into a state of rigidity, and a clonic phase, during which various muscles may cause violent thrashing motions.<sup>42,63</sup> Brain activity is depressed during the postictal period, during which the individual is usually unconscious and subdued. This is usually followed by a period in which the individual is semiconscious and very restless, usually sleeping on and off for as little as 15 min or as long as an hour or more. Afterward he or she often becomes suddenly alert and complains of no more than fatigue, muscular soreness, and possibly a headache. After an O<sub>2</sub> toxicity convulsion the individual usually remembers clearly the events up to the moment when consciousness was lost, but remembers nothing of the convulsion itself and little of the postictal phase.<sup>64</sup>

Convulsions unrelated to O<sub>2</sub> toxicity may also occur in HBO<sub>2</sub> environments and would present identically to a HBO<sub>2</sub>-induced seizure. It is critical to differentiate seizures resulting from hyperbaric oxygen from other etiologies, such as hypoglycemia. A convulsion due to O<sub>2</sub> toxicity has little lasting effects, assuming the O<sub>2</sub> pressure is immediately decreased; however, a hypoglycemic seizure unrecognized and untreated can be fatal. Unlike other tonic-clonic seizures, such as those seen in epilepsy, the danger of hypoxia during breathholding in the tonic phase of a HBO<sub>2</sub>-induced convulsion is minimized by the high PO<sub>2</sub> in the brain and tissues; the source of the toxicity helps minimize hypoxia in the tissue during the seizure. A greater danger is posed by decreasing pressure in a chamber too quickly, which could potentially lead to a gas embolism. Since it would be difficult to differentiate between a postictal individual and an unconscious victim suffering from a cerebral arterial gas embolism, those experiencing O<sub>2</sub>-induced seizures in a hyperbaric chamber under pressure are generally kept at that same pressure until their convulsions cease. The PO<sub>2</sub> in such cases is diminished solely by altering the breathing gas mixture. Patients suffering from O<sub>2</sub>-induced seizures generally have full recoveries within 24 h with no lasting effects, and it is unclear whether there is increased susceptibility to future incidents of O<sub>2</sub> toxicity.<sup>11</sup>

The primary treatment for an O<sub>2</sub>-induced seizure is to lower the inspired PO<sub>2</sub>. This is accomplished by decreasing ambient pressure, switching to a breathing mixture with a lower percentage of O<sub>2</sub>, or both. Decreasing inspired PO<sub>2</sub> may not immediately reverse the effects of CNS O<sub>2</sub> toxicity and is not without risk. It is believed that the biochemical processes responsible for the toxicity remain in place for a period after the PO<sub>2</sub> has been decreased in the ambient or inspired atmosphere. The individual experiencing the toxicity is not considered clear from danger until several minutes have passed after the PO<sub>2</sub> has been decreased.<sup>34,83</sup>

In practice, the risk of acute O<sub>2</sub> toxicity is often mitigated by interspersing short periods of air amid the pure O<sub>2</sub> therapy at increased pressure commonly referred to as “air breaks.”<sup>11</sup> It is a logical measure and some species such as insects have evolved discontinuous breathing in order to minimize risks of O<sub>2</sub> toxicity even at 1 ATA.<sup>56</sup> However, there is limited clinical data to support this practice.<sup>28</sup> Some data supports the use of intermittent air breaks of 5–10 min to prolong HBO<sub>2</sub> exposure prior to the onset of seizures.<sup>24</sup> Yet, animal models demonstrate the possibility that the rapid decreases in PO<sub>2</sub> may actually instigate seizure activity<sup>14</sup> while appearing to be beneficial in preventing pulmonary oxygen toxicity.<sup>55</sup> While intermittent exposures may decrease symptoms of CNS toxicity, measured molecular activities maintain prebreak levels, adding further confusion to the mechanism and success of air breaks during HBO<sub>2</sub>T.<sup>64</sup> Therefore, understanding the mechanisms leading to HBO<sub>2</sub> CNS toxicity can help to mitigate toxicity.

A search of current work on this subject including PubMed searches using the words “hyperbaric seizure” and “hyperbaric convulsion” yielded hundreds of peer-reviewed publications pertaining to HBO<sub>2</sub> seizures. Several reviews and case series exist that emphasize the incidence of hyperbaric oxygen seizures. To the author’s knowledge there are no peer-reviewed review articles focusing on HBO<sub>2</sub> seizures. A recent review on CNS oxygen toxicity was written in 2004.<sup>11</sup> This review emphasizes primary research into the underlying mechanism by which increased PO<sub>2</sub> causes HBO<sub>2</sub> seizures in humans. While this review is not exhaustive, its goal is to summarize the majority of the existing knowledge on this topic by adequately sampling current research.

### Mechanisms

Methods and models used to investigate the mechanisms of HBO<sub>2</sub> toxicity on the nervous system must attempt to isolate two interdependent variables: 1) effects due to the increased ambient pressure on the CNS; and 2) effects due to the increased PO<sub>2</sub>. Small mammals serve as a good animal model for studying the cellular mechanisms of oxidative stress in the mammalian central nervous system.<sup>2</sup> Therefore, many research studies have used mice, rats or other small rodents as models for research.<sup>68,117</sup>

The normobaric hyperoxic brain slice model is a common research model. It is a less desirable model to study the effects of oxygen toxicity on neuronal activity since most in vitro preparations of CNS tissue and cells use a 95% O<sub>2</sub> control level during preparation. Humans inspiring normobaric air have relatively low PO<sub>2</sub> in their brain, 35 mmHg or less, depending on the region.<sup>19</sup> Murine brains have even lower ranges of PO<sub>2</sub> in their brain, from 5 to 25 mmHg.<sup>126</sup> Direct investigation using hyperbaric oxygen is preferred.

The use of in vitro electrophysiological methods to investigate the cellular mechanisms of O<sub>2</sub> toxicity within a hyperbaric chamber has been limited by the challenges of working with or in a sealed pressure chamber and the mechanical disturbances experienced during tissue compression. Chamber design improvements have minimized these obstacles, allowing easier

experimentation on animal models in ambient pressures around 5 ATA. Refinements in chamber design and using an ambient atmosphere of 100% helium have allowed intracellular experiments in rat brain slices. Electrophysiological studies on rat neurons have shown that increases in the  $\text{Po}_2$  in cerebral tissue lead to increased ROS production, followed by increased cortical EEG activity, and finally resulting in the onset of an  $\text{O}_2$ -induced seizure activity.<sup>37,108</sup>

Effects on the CNS attributed to increased hydrostatic pressure, such as high-pressure nervous syndrome,<sup>37</sup> tend to occur at very high pressures, ranging from 15 to 70 ATA. This results from compression of cerebral spinal fluid, circulation, and extracellular and intracellular fluid compartments of the CNS. Cellular mechanisms most likely involve synaptic and membrane dynamic responses to severe and fast changes in pressure.<sup>33,37</sup> Therefore there is little evidence to suggest that hydrostatic pressure plays a significant role in  $\text{HBO}_2$  seizures, particularly at pressures involved with  $\text{HBO}_2\text{T}$  less than 3 ATA.<sup>33</sup>

A relationship exists between high pressures and glycine receptors which indicates possible roles pressure plays on  $\text{HBO}_2$  seizures. High pressures have no effect on the maximum response of the glycine receptor to glycine; however, the half maximal effective concentration of glycine to its receptor and pressure become directly proportional at pressures above 100 ATA.<sup>101</sup> While this seems less likely to be correlated with seizures occurring at 2–3 ATA, typical of  $\text{HBO}_2\text{T}$ , it appears to be associated with high pressure neurological syndrome at much greater depths.<sup>37,101</sup> The fact that glycine receptors are linked to myoclonic activity in mammals raises suspicion that conformational alterations at pressures less than 100 ATA may still participate in hyperbaric seizures to some degree at lower pressures.<sup>76</sup>

$\text{O}_2$  under hyperbaric conditions behaves like a drug whose effects on metabolism exceed  $\text{O}_2$ 's common role as a simple oxidizer.<sup>64</sup> The molecular effects of increased  $\text{Po}_2$  during  $\text{HBO}_2\text{T}$  affects neural networks in the CNS, resulting in overall network excitability.<sup>37</sup> Much of the research into the molecular mechanisms of CNS  $\text{O}_2$  toxicity has focused on the neuroexcitatory and neuroinhibitory effects of neuroactive agents that results from elevated  $\text{Po}_2$ . In general, mechanisms responsible for hyperbaric oxygen seizures can be categorized to include: ROS, inhibitory neurotransmitters, excitatory neurotransmitters, extracellular effects resulting in neurotransmitter dysregulation, and the imbalance of neuroprotective mechanisms.

Oxidative stress plays a key role in the mechanism of  $\text{O}_2$  toxicity. CNS  $\text{O}_2$  toxicity is an acute exposure to an oxidative environment disrupting neurological function.  $\text{HBO}_2\text{T}$  greatly increases oxygen tension in the brain. Molecular  $\text{O}_2$  is a natural oxidative reagent in cellular biochemical pathways producing various free radicals. The mammalian CNS response to hyperoxia ranges from moderate, reversible changes in neural activity to violent seizures that may lead to irreversible motor deficits and death. In vitro experiments on rat brains exposed to  $\text{HBO}_2$  demonstrate that the  $\text{Po}_2$  is directly proportional to ROS formation in the tissue.<sup>108</sup> The initial physiological response to

hyperoxia is increased formation of superoxide and nitric oxide (NO) among other ROS.<sup>105</sup> Prolonged exposure of neural tissue to  $\text{HBO}_2$  stresses antioxidant protective mechanisms. Oxidation of cellular components occurs due to the increased production of free radicals such as superoxide, hydrogen peroxide, hydroxyl radicals, and peroxynitrite. Oxidation of cellular metabolic reactants has therapeutic benefits,<sup>104,105</sup> but also has negative effects. ROS can cause membrane weakening and metabolic dysregulation if normobaric  $\text{O}_2$  is not restored. It directly affects the various ionic conductances that regulate cell excitability. ROS are also reported to target neurotransmitter systems, altering chemical synaptic transmission.<sup>34,37</sup> The network of ROS and antioxidants remains unclear and requires further research.<sup>123</sup>

The body scavenges oxidizing substances through enzymatic antioxidants such as superoxide dismutase for superoxide anions, catalase for hydrogen peroxide and nonenzymatic antioxidants such as reduced glutathione and vitamin E.<sup>105</sup> Glutathione is regenerated by reaction with nicotinamide adenine dinucleotide phosphate (NADPH). Therefore, sufficient levels of both glutathione and NADPH may be critical to defending against the increased level of oxidants.<sup>34</sup>

Nonenzymatic antioxidants should logically protect against  $\text{HBO}_2$  seizures. Vitamin E deficiency increases the risk of  $\text{HBO}_2$  seizures<sup>15</sup>; however, vitamin E failed to prevent  $\text{HBO}_2$  seizures.<sup>123</sup> Another example is superoxide dismutase. Superoxide catalyzes superoxide anions to  $\text{O}_2$ . Therefore, increased levels or activity of superoxide dismutase should decrease levels of ROS; hence, in theory,  $\text{HBO}_2$  seizures should be attenuated.<sup>57,93</sup> However, in transgenic mice bred to overexpress human extracellular superoxide dismutase in the brain, inhibition of superoxide dismutase increased resistance to  $\text{HBO}_2$  seizures contrary to expectations. By inhibiting superoxide dismutase, the catalysis of superoxide into  $\text{O}_2$  (an in vivo antioxidant mechanism) is blocked, allowing superoxide levels to rise unopposed during  $\text{HBO}_2$  exposure. A fourfold decrease in seizures was measured in these mice pretreated with diethyldithiocarbamate, an inhibitor of human extracellular superoxide dismutase.<sup>88</sup> The mechanism of this counterintuitive result appears to be the interaction between superoxide and other  $\text{HBO}_2$ -induced reactants.

Gamma-aminobutyric acid (GABA) has long been correlated with  $\text{HBO}_2$  seizures.<sup>120,121</sup> Though GABA has been found to be lowered in mammalian neuronal synapses during  $\text{HBO}_2$  seizures when exposed to  $\text{HBO}_2$  in short intervals,<sup>58</sup> there is evidence to suggest that the increased steady-state levels of GABA over longer intervals may be responsible for  $\text{O}_2$ -induced seizures.<sup>46</sup> In experiments involving transgenic mice with a  $\text{HBO}_2$ -sensitivity phenotype, data suggests that the excitatory amino acids, such as aspartate and glutamate, play as important or more important roles in  $\text{HBO}_2$  seizures than GABA.<sup>81</sup>

Glutamate, an excitatory amino acid, is a potent, fast-acting neurotoxin in neuronal cultures. It has been shown to create morphological changes in mature cortical neurons within minutes of  $\text{HBO}_2$  exposure with neuronal degeneration occurring over the course of hours. In vitro experiments demonstrated that one-hundredth the intracellular concentration of



glutamate during hyperbaric exposures critically damages cortical neurons.<sup>27</sup> Decreased glutamate metabolism during HBO<sub>2</sub> exposure sensitizes neural networks to HBO<sub>2</sub> seizures.<sup>72</sup> Conflicting evidence exists as to the degree of change in excitatory amino acids prior to and during HBO<sub>2</sub> seizures. Recent evidence suggests that O<sub>2</sub>-induced seizures may result from an imbalance of excitatory and inhibitory synaptic neurotransmitters, glutamate and GABA, respectively. The imbalance results in a greater relative decrease in presynaptic release of GABA than of glutamate,<sup>38</sup> which suggests that the relative increase of excitatory neurotransmitters with respect to inhibitory neurotransmitters may be a basic mechanism of HBO<sub>2</sub> seizures.

Extracellular mediators of physiological functions such as NO also play a role in HBO<sub>2</sub> seizures. NO has been implicated in neurotoxicities resulting from excess glutamate stimulation in cultures of rat cortex, striatum, and hippocampus.<sup>36</sup> NO activity appears to increase the ratio of excitatory to inhibitory neurotransmitters which increases the probability of O<sub>2</sub> seizures.<sup>38</sup> Neurons containing nitric oxide synthase (NOS), widespread throughout the cortex, react to HBO<sub>2</sub> by increasing NO production.<sup>1,82</sup> In HBO<sub>2</sub> environments, NO acutely decreases cerebral blood flow but then increases regional cerebral blood flow after prolonged HBO<sub>2</sub> exposure preceding neuronal excitation.<sup>39,51</sup> NO has been associated with changes in cerebral blood flow and HBO<sub>2</sub> seizures.<sup>98</sup> Cerebral blood flow is indirectly proportional to the time of onset of HBO<sub>2</sub> seizures in animal models. Effects of NO with respect to HBO<sub>2</sub> seizures is diagrammed in **Fig. 1**.<sup>68,125</sup> When interstitial NO, aspartate, glutamate, and GABA were measured in vivo in anesthetized rats under HBO<sub>2</sub> conditions with respect to blood flow and EEG activity of the striatum, increases in NO metabolites and blood preceded spikes in EEG activity and seizures. Thus, it was concluded that HBO<sub>2</sub>-stimulated neuronal NO production promoted an imbalance between excitatory (glutamate) and inhibitory (GABA) synaptic activity. This in turn contributes to O<sub>2</sub>-induced seizures in rats.<sup>38</sup>

The molecular mechanisms involved in HBO<sub>2</sub> seizures are complex. An imbalance of the redundant molecular protective mechanisms that humans have evolved to counter deleterious effects of increased Po<sub>2</sub>, as depicted in **Fig. 2**, appears to lead to HBO<sub>2</sub> seizures. Elevated Po<sub>2</sub> causes concomitant saturation of


the redundant antioxidant systems evolved to protect humans. Though individual reactions are well-described, the network of interactions between the various reactions are not well-described.<sup>123</sup> Increased Po<sub>2</sub> saturates enzymes and maximizes rates of reactions designed to protect against reactive species. For example increased Po<sub>2</sub> saturates superoxide dismutase, increasing superoxide. Superoxide anions can react with NO to yield nitrate (NO<sub>3</sub>), a neurologically inert substance; however, the rate of this reaction does not appear sufficient to eliminate risks of CNS O<sub>2</sub> toxicity at sufficiently high Po<sub>2</sub> over time.

A long-standing question regarding hyperbaric oxygen seizures is whether certain regions of the CNS are more susceptible to HBO<sub>2</sub>.<sup>112</sup> Neuroanatomic studies have shown that centrally located regions of the brain are most affected by exposure to HBO<sub>2</sub>, including: the globus pallidus, substantia nigra, superior olivary nucleus, ventral cochlear nucleus, limbic structures, amygdala, and the spinal cord gray matter, diagrammed in **Fig. 3**.<sup>109,111</sup> It is worth noting that the globus pallidus and substantia nigra are brain regions also susceptible to CO toxicity. Single-cell electrophysiology experiments have shown that hippocampus and brain stem neurons are disproportionately sensitive to increased Po<sub>2</sub> in surrounding tissues when exposed to HBO<sub>2</sub>.<sup>50,65</sup> The anatomical localization of neuroactive agents and their effects may also explain anatomical distribution of increased O<sub>2</sub> sensitization.<sup>37,90</sup>


For example, at HBO<sub>2</sub> levels of 3-5 ATA, regional cerebral blood flow in the substantia nigra decreased for 30 min but gradually returned to normal levels preceding EEG spikes.<sup>33</sup> Acute exposure to HBO<sub>2</sub> results in an increased firing rate of specific neurons, particularly carbon dioxide (CO<sub>2</sub>)/proton-chemosensitive neurons, which are coupled via gap junctions and baroreceptors, in the cerebral and cerebella cortex that demonstrate a high sensitivity to HBO<sub>2</sub>, chemical oxidants, and neurotransmitters.<sup>33,40,80</sup>

Certain conditions heighten one's risk to CNS toxicity and HBO<sub>2</sub> seizures. Hypercapnia elevates the risk of O<sub>2</sub> toxicity.<sup>100,119</sup> Hypercapnic-induced intracellular acidosis makes cells more susceptible to ROS. CO<sub>2</sub> causes cerebral vasodilation, increases cerebral blood flow, and heightens CNS exposure to elevated Po<sub>2</sub>. Neurons in the solitary complex are particularly susceptible to increased PCO<sub>2</sub> and Po<sub>2</sub>, resulting in an increased rate of excitatory firing. Increased PCO<sub>2</sub> in HBO<sub>2</sub> environments may occur by: 1) a decrease in CO<sub>2</sub>-carrying capacity of venous hemoglobin since venous hemoglobin may be saturated with O<sub>2</sub>; 2) alveolar hypoventilation and CO<sub>2</sub> retention; and 3) CO<sub>2</sub>-contamination due to inadequate scrubbing of recirculated breathing gas.<sup>37,100</sup> Exercise also increases the risk of CNS O<sub>2</sub> toxicity, likely related to increased cerebral blood flow and metabolic rate.<sup>2,66</sup> CO toxicity significantly increases the risk of HBO<sub>2</sub> seizures.<sup>52,97</sup>

Current preventative measures to counter O<sub>2</sub> toxicity include minimizing exposure times to increased Po<sub>2</sub>, decreasing the inspired Po<sub>2</sub>, or inserting periods of air breaks.<sup>11</sup> There is evidence in animal models to suggest that repeated HBO<sub>2</sub> exposures increases risk of seizures.<sup>6,48,75</sup> Data support brain derived neurotrophic factor, 7-nitroindazol (7-NI), and NO as potential



**Fig. 1.** Schematic of extracellular interactions produced by increased Po<sub>2</sub> that result in CNS HBO<sub>2</sub> seizures. Increased cerebral blood flow (CBF) results in decreased time to onset of HBO<sub>2</sub> seizures (tHBO<sub>2</sub>S). Extracellular substances such as phosphodiesterase-5 inhibitors (PDE-5i), 7-NI, N-nitro-L-arginine (NNA, a NOS inhibitor), and daurisorline (DSL, a calcium channel blocker) affect CBF. Dotted line = lessened action (-). Bold line = increased action (+). Large arrow = correlation.



**Fig. 2.** Schematic of some synaptic changes produced by increased  $P_{O_2}$  and resulting in CNS  $HBO_2$  seizures. The human body has several equilibrated safeguards that minimize effects of ROS on neural networks. Increased  $P_{O_2}$  appears to saturate protective enzymes and unfavorably shift protective reactions in the direction of neural network overstimulation, resulting in  $HBO_2$  seizures. NT = neurotransmitter; AP = action potential. Dotted line = lessened action. Bold line = increased action.


mechanisms for sensitization to repeated  $HBO_2$  seizures.<sup>20,25,26,60</sup> Yet there appears to be some randomization to susceptibility. An individual may repeat the same exposure conditions and suffer from CNS  $O_2$  toxicity for no apparent reason.<sup>11</sup>

Since the mechanism of CNS  $O_2$  toxicity remains uncertain, there is a paucity of prophylactic measures to prevent it. Certain factors are known to mitigate an individual's susceptibility to CNS  $O_2$  toxicity. Numerous prophylactic treatments for  $HBO_2$ -induced seizures have been shown to be effective through in vivo experiments involving rats and mice.

NO is an important mediator of CNS  $O_2$  toxicity.<sup>12</sup> Inhibition of NOS with nitroarginine showed similar prevention of CNS toxicity and  $O_2$ -induced seizures in both transgenic and nontransgenic mice.<sup>23,88,115</sup> The potency of NOS inhibitors in preventing CNS  $O_2$  toxicity is indirectly proportional to the dissociation constant of the inhibitor and NOS.<sup>36</sup> Intraperitoneal administration of GABA proved effective in protecting rats from  $O_2$ -induced seizures. Since GABA does not cross the blood brain barrier, the mechanism of its protection is speculated to be an osmotic effect drawing a metabolite of GABA out of the

brain.<sup>46</sup> Pretreatment of rats exposed to  $HBO_2$  conditions with 7-NI slowed the rate of decline in GABA levels, decreased the glutamate/GABA excitotoxicity index, and minimized EEG spikes associated with  $O_2$  toxicity.<sup>38</sup>

MK-801, an NMDA receptor antagonist, has been shown to prevent EEG spikes associated with  $O_2$  toxicity and  $O_2$ -induced seizures.<sup>37,39</sup> Other substances such as disulfiram (Antabuse)<sup>21,47,117</sup> and antioxidants also appear to delay or diminish  $O_2$  toxicity in the brain.<sup>34,37</sup> Additional agents that hasten the onset or increase incidence of  $HBO_2$  seizures include: adrenocortical hormones, epinephrine, hyperthermia, norepinephrine, thyroid hormones, vitamin E deficiency,<sup>15</sup> brain derived neurotrophic factor,<sup>25</sup> misonidazole,<sup>54</sup> pseudoephedrine,<sup>91</sup> hyperglycemia,<sup>4</sup> and phosphodiesterase-5 inhibitors.<sup>41</sup> Additional agents that delay the onset or attenuate  $HBO_2$  seizures include: N-nitro-L-arginine (NNA),<sup>22,115</sup> daurisolone (DSL),<sup>115</sup> acclimatization to hypoxia, antioxidants,<sup>74</sup> chlorpromazine, reserpine, starvation,<sup>31</sup> ganglionic blocking drugs and anti-epileptics,<sup>71</sup> glutathione,<sup>62</sup> hypothermia, hypothyroidism, insulin,<sup>4</sup> CoQ10 and carnitine,<sup>7</sup> acetazolamide,<sup>119</sup> excitatory



**Fig. 3.** Brain regions most likely involved in HBO<sub>2</sub>-induced seizures. Certain regions of the CNS (including the solitary complex in the dorsal medulla, hippocampus, globus pallidus, substantia nigra, superior olivary nucleus, ventral cochlear nucleus, and spinal cord gray matter) appear more susceptible than others to these effects. Note the central nature of these regions, anatomically similar to CO susceptible regions.

amino acid antagonists,<sup>30</sup> aminooxyacetic acid (AAOA),<sup>5,35</sup> delta-sleep-inducing peptide (DSIP),<sup>78</sup> beta-carotene,<sup>10</sup> vigabatrin,<sup>53,110</sup> propionyl-L-carnitine,<sup>8</sup> leukotriene and PAF inhibitors,<sup>73</sup> carbamazepine,<sup>95</sup> propranolol,<sup>117</sup> caffeine,<sup>13</sup> Dilantin,<sup>116</sup> and lithium.<sup>103</sup> Some agents that one would expect to affect HBO<sub>2</sub> seizures, such as allopurinol and pyridoxine, did not.<sup>57,103,114</sup>

### Potential Areas of Research

A significant amount of research has been conducted on the mechanisms of CNS O<sub>2</sub> toxicity, but few clinical studies or trials exist as to how to prevent it. There are few attempts in applying existing results to testing prophylactic treatments for humans. This is likely due to the potential difficulties of such studies. A search (using keywords “hyperbaric oxygen,” “hyperbaric oxygen therapy,” and “oxygen toxicity”) shows over 50 active NIH-funded clinical trials pertaining to HBO<sub>2</sub> and only one pertaining to CNS O<sub>2</sub> toxicity.<sup>86</sup> Potentially beneficial, “off-the-shelf” medications (FDA approved medication or nonregulated supplement) could be trialed for their efficacy in preventing or reducing the incidence of HBO<sub>2</sub>-induced CNS toxicity, including: disulfiram (an inhibitor of alcohol dehydrogenase with some evidence of success in preventing HBO<sub>2</sub> seizures in animal models, approved for use in the treatment of alcohol abuse),<sup>34</sup> acamprosate (a glutamate receptor modulator approved for use in the treatment of alcohol abuse), and vitamin E (a nonenzymatic antioxidant sold as a supplement).

In a clinical setting, an HBO<sub>2</sub>T center would have no less than 1000 treatments per year. If we assume that treatments can be taken as independent events, i.e., there is no correlation between two treatments on the same person or different individuals with the same preexisting conditions, then we can use all 1000 treatments as individual events upon which we can base our design. This is purely an assumption in order to minimize a sample size calculation. An O<sub>2</sub>-induced seizure is the

most easily quantifiable endpoint for measuring CNS oxygen toxicity, although any signs, symptoms, or composite of the two could be used.

The frequency of an oxygen-induced seizure may be approximated at 1 in 10,000 treatments, with the literature citing a wide range from 2 in 100,000 to 1 in 1000.<sup>97,118,124</sup> One study estimates the probability of a CNS toxicity event as low as 1.7% over the period of a 4-h dive with Po<sub>2</sub> = 1.4 ATA.<sup>102</sup>

A prospective study would seek to decrease the frequency of oxygen-induced seizures by a given factor as a result of implementing a prophylactic treatment, such as disulfiram or antioxidants.

Using STATA version 9.0 for Windows (Stata Corporation, College Station, TX) the sample size needed to conduct a definitive randomized trial demonstrating a tenfold reduction in the frequency of hyperbaric oxygen-induced seizures, from 0.0001 to 0.00001, using a two-sided 0.05 level test with 80% power is 85,218, assuming equal allocation to the experimental and control arms. It could take a single hyperbaric facility over a decade to accrue enough data to execute a definitive study of this nature. This information necessitates that randomized clinical studies investigating CNS oxygen toxicity be multicenter studies with endpoints more than just seizures used to identify oxygen-toxicity.

Further, agents that mitigate O<sub>2</sub>-induced seizures may also negatively affect the therapeutic benefits of HBO<sub>2</sub>T, thus adding to the complexity of the study. For example, any antioxidant that can effectively eliminate ROS during HBO<sub>2</sub>T may eliminate their role in causing HBO<sub>2</sub> seizures, but it would also eliminate the benefits ROS play in promoting wound healing and postischemic tissue survival.<sup>105</sup> This would require a long time, a great deal of resources, and/or multiple institutions to accomplish. It is unlikely for a research study of this magnitude to occur. Therefore, continued basic science research may be the best alternative to investigate CNS toxicity.

The advent of nanoscale devices allows for more precise delivery and investigation of mediators of O<sub>2</sub>-induced seizures such as NO.<sup>96</sup> The excitatory firing rate of dorsal medullary neurons due to HBO<sub>2</sub> can be mimicked by the presence of pro-oxidants at normobaric conditions,<sup>37</sup> demonstrating that normobaric experimentation might be feasible to shed light on O<sub>2</sub>'s toxic effects under pressure. Precise delivery of ROS or neurotransmitter mediators of CNS toxicity would allow for detailed experimental designs at the molecular, neuronal level in normal models at normobaric conditions. This may shed light on unanswered questions such as whether the effects of hyperoxia and the resulting ROS are presynaptic or postsynaptic

in origin, currently an unanswered question. Normobaric models of the effects of HBO<sub>2</sub> would also open the door to the wide array of experimental tools that otherwise would not be feasible to perform in hyperbaric chambers. Finally, as data and proposed theories of O<sub>2</sub> toxicity increase, this area of research becomes primed for computational simulations. Current prediction models have shown that it is very difficult to build a prediction model for mild hyperoxia given the current data.<sup>102</sup> However, computational analysis and simulations of molecular signaling interactions might enable existing and otherwise conflicting theories to coexist within a new model for CNS O<sub>2</sub> toxicity. This would provide a physiologically based model with greater precision and accuracy. Models of complex biological systems such as T lymphocyte activation demonstrate the feasibility of this approach.<sup>59</sup>

### Summary

The benefits of HBO<sub>2</sub> come with the risk of CNS O<sub>2</sub> toxicity. The exact mechanism of O<sub>2</sub> toxicity remains a mystery. Prophylactic measures and treatment for CNS O<sub>2</sub> toxicity remain centered on limiting exposure to high PO<sub>2</sub>. Better understanding of molecular mechanisms causing O<sub>2</sub> toxicity can lead to prophylactic therapies for consideration in clinical trials. There is increasing need for research on the systemic interactions of the multiple players involved in HBO<sub>2</sub> seizures in order to better understand how they occur and how to prevent them.

### REFERENCES

- Allen BW, Demchenko IT, Piantadosi CA. Two faces of nitric oxide: implications for cellular mechanisms of oxygen toxicity. *J Appl Physiol*. 2009 Feb 106(2):662–667.
- Arieli R. Oxygen toxicity is not related to mammalian body size. *Comp Biochem Physiol A Comp Physiol*. 1988; 91(2):221–223.
- Arieli R, Arieli Y, Daskalovic Y, Eynan M, Abramovich A. CNS oxygen toxicity in closed-circuit diving: signs and symptoms before loss of consciousness. *Aviat Space Environ Med*. 2006; 77(11):1153–1157.
- Beckman DL, Crittenden DJ, Overton 3rd DH, Blumenthal SJ. Influence of blood glucose on convulsive seizures from hyperbaric oxygen. *Life Sci*. 1982; 31(1):45–49.
- Beckman DL, Iams SG. Protection against high-pressure oxygen seizures by amino-oxyacetic acid. *Undersea Biomed Res*. 1978 Sep 5(3):253–257.
- Benjamini Y, Bitterman N. Statistical approach to the analysis of sensitivity to CNS oxygen toxicity in rats. *Undersea Biomed Res*. 1990 May 17(3):213–221.
- Bertelli A, Giovannini L, Mian M, Spaggiari PG. Protective action of propionyl-L-carnitine on toxicity induced by hyperbaric oxygen. *Drugs Exp Clin Res*. 1990; 16(10):527–530.
- Bertelli A, Bertelli AA, Giovannini L, Spaggiari P. Protective synergic effect of coenzyme Q10 and carnitine on hyperbaric oxygen toxicity. *Int J Tissue React*. 1990; 12(3):193–196.
- Bitterman N, Laor A, Melamed Y. CNS oxygen toxicity in oxygen-inert gas mixtures. *Undersea Biomed Res*. 1987 Nov 14(6):477–483.
- Bitterman N, Melamed Y, Ben-Amotz A. Beta-carotene and CNS oxygen toxicity in rats. *J Appl Physiol* (1985). 1994 Mar 76(3):1073–1076.
- Bitterman N. CNS oxygen toxicity. *Undersea Hyperb Med*. 2004; 31(1):63–72.
- Bitterman N, Bitterman H. L-arginine-NO pathway and CNS oxygen toxicity. *J Appl Physiol* (1985). 1998; 84(5):1633–1638.
- Bitterman N, Schaal S. Caffeine attenuates CNS oxygen toxicity in rats. *Brain Res*. 1995; 696(1-2):250–3.
- Bleiberg B, Kerem D. Central nervous system oxygen toxicity in the resting rat: postponement by intermittent oxygen exposure. *Undersea Biomed Res*. 1988 Sep 15(5):337–52.
- Block ER. Effect of superoxide dismutase and succinate on the development of hyperbaric oxygen toxicity. *Aviat Space Environ Med*. 1977 Jul 48(7):645–8.
- Boerema I, Kroll JA, Meijne NG, Lobin E, Kroon B, Huskies JW. High atmospheric pressure as an aid to cardiac surgery. *Arch Chir Neerl*. 1956; 8:193–211.
- Camporesi EM, Bosco G. Mechanisms of action of hyperbaric oxygen therapy. *Undersea Hyperb Med*. 2014; 41(3):247–252.
- Camporesi EM. Side effects of hyperbaric oxygen therapy. *Undersea Hyperb Med*. 2014; 41(3):253–257.
- Carreau A, El Hafny-Rahbi B, Matejuk A, Grillon C, Kieda C. Why is the partial oxygen pressure of human tissues a crucial parameter? Small molecules and hypoxia. *J Cell Mol Med*. 2011; 15(6):1239–1253.
- Chavko M, Auker CR, McCarron RM. Relationship between protein nitration and oxidation and development of hyperoxic seizures. *Nitric Oxide*. 2003 Aug 9(1):18–23.
- Chavko M, Braisted JC, Harabin AL. Attenuation of brain hyperbaric oxygen toxicity by fasting is not related to ketosis. *Undersea Hyperb Med*. 1999; 26(2):99–103.
- Chavko M, Braisted JC, Harabin AL. Effect of MK-801 on seizures induced by exposure to hyperbaric oxygen: comparison with AP-7. *Toxicol Appl Pharmacol*. 1998; 151(2):222–228.
- Chavko M, Braisted JC, Outsas NJ, Harabin AL. Role of cerebral blood flow in seizures from hyperbaric oxygen exposure. *Brain Res*. 1998; 791(1-2):75–82.
- Chavko M, McCarron RM. Extension of brain tolerance to hyperbaric O<sub>2</sub> by intermittent air breaks is related to the time of CBF increase. *Brain Res*. 2006; 1084(1):196–201.
- Chavko M, Nadi NS, Keyser DO. Activation of BDNF mRNA and protein after seizures in hyperbaric oxygen: implications for sensitization to seizures in re-exposures. *Neurochem Res*. 2002; 27(12):1649–1653.
- Chavko M, Xing G, Keyser DO. Increased sensitivity to seizures in repeated exposures to hyperbaric oxygen: role of NOS activation. *Brain Res*. 2001; 900(2):227–233.
- Choi DW, Maulucci-Gedde M, Kriegstein AR. Glutamate neurotoxicity in cortical cell culture. *J Neurosci*. 1987 Feb 7(2):357–368.
- Clark JM. Extension of oxygen tolerance by interrupted exposure. *Undersea Hyperb Med*. 2004; 31(2):195–198.
- Clark JM. The toxicity of oxygen. *Am Rev Respir Dis*. 1974; 110(6, Pt 2): 40–50.
- Colton CA, Colton JS. Blockade of hyperbaric oxygen induced seizures by excitatory amino acid antagonists. *Can J Physiol Pharmacol*. 1985; 63(5):519–521.
- D'Agostino DP, Pilla R, Held HE, Landon CS, Puchowicz M, et al. Therapeutic ketosis with ketone ester delays central nervous system oxygen toxicity seizures in rats. *Am J Physiol Regul Integr Comp Physiol*. 2013; 304(10):R829–R836.
- D'Agostino Dias M, Fontes B, Poggetti RS, Birolini D. Hyperbaric oxygen therapy: types of injury and number of sessions—a review of 1506 cases. *Undersea Hyperb Med*. 2008; 35(1):53–60.
- Daniels S. Cellular and neurophysiological effects of high ambient pressure. *Undersea Hyperb Med*. 2008; 35(1):11–19.
- Davis JC, Hunt TK, editors. *Hyperbaric oxygen therapy*. Bethesda (MD): Undersea Medical Society, Inc.; 1977.
- Davison AJ. Amino-oxyacetic acid provides transient protection against seizures induced by hyperbaric oxygen. *Brain Res*. 1983; 276(2):384–387.
- Dawson VL, Dawson TM, Bartley DA, Uhl GR, Snyder SH. Mechanisms of nitric oxide-mediated neurotoxicity in primary brain cultures. *J Neurosci*. 1993; 13(6):2651–2661.
- Dean JB, Mulkey DK, Garcia AJ, Putnam RW, Henderson RA. Neuronal sensitivity to hyperoxia, hypercapnia, and inert gases at hyperbaric pressures. *J Appl Physiol* (1985). 2003; 95:883–909.



38. Demchenko IT, Piantadosi CA. Nitric oxide amplifies the excitatory to inhibitory neurotransmitter imbalance accelerating oxygen seizures. *Undersea Hyperb Med.* 2006; 33(3):169–174.
39. Demchenko IT, Boso AE, O'Neill TJ, Bennett PB, Piantadosi CA. Nitric oxide and cerebral blood flow responses to hyperbaric oxygen. *J Appl Physiol* (1985). 2000; 88(4):1381–1389.
40. Demchenko IT, Gasier HG, Zhilyaev SY, Moskvina AN, Krivchenko AI, et al. Baroreceptor afferents modulate brain excitation and influence susceptibility to toxic effects of hyperbaric oxygen. *J Appl Physiol* (1985). 2014; 117(5):525–534.
41. Demchenko IT, Ruehle A, Allen BW, Vann RD, Piantadosi CA. Phosphodiesterase-5 inhibitors oppose hyperoxic vasoconstriction and accelerate seizure development in rats exposed to hyperbaric oxygen. *J Appl Physiol* (1985). 2009 Apr 106(4):1234–1242.
42. Domachevsky L, Rachmany L, Barak Y, Rubovitch V, Abramovich A, Pick CG. Hyperbaric oxygen-induced seizures cause a transient decrement in cognitive function. *Neuroscience.* 2013; 247:328–334.
43. Donald K. Oxygen and the diver. West Palm Beach (FL): Best Publishing Co.; 1995.
44. Eckenhoff RG, Dougherty JH, Jr., Messier AA, Osborne SF, Parker JW. Progression of and recovery from pulmonary oxygen toxicity in humans exposed to 5 ATA air. *Aviat Space Environ Med.* 1987 Jul 58(7):658–667.
45. Eynan M, Krinsky N, Biram A, Arieli Y, Arieli R. A comparison of factors involved in the development of central nervous system and pulmonary oxygen toxicity in the rat. *Brain Res.* 2014; 1574:77–83.
46. Faiman MD, Nolan RJ, Baxter CF, Dodd DE. Brain gamma-aminobutyric acid, glutamic acid decarboxylase, glutamate, and ammonia in mice during hyperbaric oxygenation. *J Neurochem.* 1977 Apr 28(4):861–865.
47. Faiman MD, Nolan RJ, Oehme FW. Effect of disulfiram on oxygen toxicity in beagle dogs. *Aerospace Med.* 1974 Jan 45(1):29–32.
48. Fenton LH, Robinson MB. Repeated exposure to hyperbaric oxygen sensitizes rats to oxygen-induced seizures. *Brain Res.* 1993; 632(1-2): 143–9.
49. Fock AW. Analysis of recreational closed-circuit rebreather deaths 1998–2010. *Diving Hyperb Med.* 2013; 43:78–85.
50. Garcia AJ 3rd, Putnam RW, Dean JB. Hyperbaric hyperoxia and normobaric reoxygenation increase excitability and activate oxygen-induced potentiation in CA1 hippocampal neurons. *J Appl Physiol* (1985). 2010;109(3):804–819.
51. Gutsaeva DR, Moskvina AN, Zhiliaev SIu, Kostkin VB, Demchenko IT. [Nitric oxide and carbon dioxide in neurotoxicity induced by oxygen under pressure]. [Article in Russian]. *Russ Fiziol Zh Im I M Sechenova.* 2004; 90(4):428–436.
52. Hampson NB, Simonson SG, Kramer CC, Piantadosi CA. Central nervous system oxygen toxicity during hyperbaric treatment of patients with carbon monoxide poisoning. *Undersea Hyperb Med.* 1996 Dec 23(4):215–219.
53. Hall AA, Young C, Bodo M, Mahon RT. Vigabatrin prevents seizure in swine subjected to hyperbaric hyperoxia. *J Appl Physiol* (1985). 2013; 115(6):861–867.
54. Harris JW, Shrieve DC. Misonidazole (Ro-07-0582) sensitizes mice to convulsions induced by hyperbaric oxygen or pentylene-tetrazol. *Br J Radiol.* 1978; 51(612):1024–1025.
55. Hendricks PL, Hall DA, Hunter WL, Jr., Haley PJ. Extension of pulmonary O<sub>2</sub> tolerance in man at 2 ATA by intermittent O<sub>2</sub> exposure. *J Appl Physiol Respir Environ Exerc Physiol.* 1977; 42(4):593–599.
56. Hetz SK, Bradley TJ. Insects breathe discontinuously to avoid oxygen toxicity. *Nature.* 2005; 433(7025):516–519.
57. Hoppe SA, Terrell DJ, Gottlieb SF. The effect of allopurinol on oxygen-induced seizures in mice. *Aviat Space Environ Med.* 1984; 55(10): 927–930.
58. Hori S. Study on hyperbaric oxygen-induced convulsion with particular reference to gamma-aminobutyric acid in synaptosomes. *J Biochem.* 1982; 91(2):443–448.
59. Jacobi Medical Center Hyperbaric Treatments [Internet]. Jacobi Medical Center, Bronx, NY; c2015 [cited 2015 Dec 15]. Available from: <http://www.jacobi-hyperbaric.com/html/hyperbaric-treatments.html>.
60. Jellestad FK, Gundersen H. Behavioral effects of 7-nitroindazole on hyperbaric oxygen toxicity. *Physiol Behav.* 2002; 76(4-5):611–616.
61. Jenkinson SG. Oxygen toxicity. *New Horiz.* 1993; 1(4):504–511.
62. Jenkinson SG, Jordan JM, Duncan CA. Effects of selenium deficiency on glutathione-induced protection from hyperbaric hyperoxia in rat. *Am J Physiol.* 1989; 257(6, Pt 1):L393–L398.
63. Kandel ER, Schwartz JH, Jessell TM. Principles of neuroscience, 4th ed. Columbus (OH): McGraw-Hill; 2000.
64. Kindwall EP, Whalen HT. Hyperbaric medicine practice, 2nd ed. Flagstaff (AZ): Best Publishing Company; 2004.
65. King GL, Parmentier JL. Oxygen toxicity of hippocampal tissue in vitro. *Brain Res.* 1983; 260(1):139–142.
66. Koch AE, Koch I, Kowalski J, Schipke JD, Winkler BE, et al. Physical exercise might influence the risk of oxygen-induced acute neurotoxicity. *Undersea Hyperb Med.* 2013; 40(2):155–163.
67. Kranke P, Bennett MH, Martyn-St James M, Schnabel A, Debus SE, Weibel S. Hyperbaric oxygen therapy for chronic wounds. *Cochrane Database Syst Rev.* 2015; 6:CD0004123.
68. Kurasako T, Takeda Y, Hirakawa M. Increase in cerebral blood flow as a predictor of hyperbaric oxygen-induced convulsion in artificially ventilated rats. *Acta Med Okayama.* 2000; 54(1):15–20.
69. Lambertsen CJ. Definition of Oxygen Tolerance in Man [Internet]. Institute For Environmental Medicine, University of Pennsylvania Medical Center Philadelphia, PA 19104-6068; Naval Medical Research and Development Command and Office of Naval Research 31 December 1987. C2015 [cited 2015 Dec 12]. Available from: <http://www.dtic.mil/dtic/tr/fulltext/u2/a239247.pdf>.
70. Lee CH, Lee L, Yang KJ, Lin TF. Top-cited articles on hyperbaric oxygen therapy published from 2000 to 2010. *Undersea Hyperb Med.* 2012; 39(6):1089–1098.
71. Lembeck F, Beubler E. Convulsions induced by hyperbaric oxygen: inhibition by phenobarbital, diazepam and baclofen. *Naunyn Schmiedeberg Arch Pharmacol.* 1977; 297(1):47–51.
72. Li Q, Guo M, Xu X, Xiao X, Xu W, et al. Rapid decrease of GAD 67 content before the convulsion induced by hyperbaric oxygen exposure. *Neurochem Res.* 2008; 33(1):185–193.
73. Lin Y, Jamieson D. Are leukotrienes or PAF involved in hyperbaric oxygen toxicity? *Agents Actions.* 1993; 38(1-2):66–75.
74. Lin Y, Jamieson D. Effects of antioxidants on oxygen toxicity in vivo and lipid peroxidation in vitro. *Pharmacol Toxicol.* 1992; 70(4):271–277.
75. Liu W, Li J, Sun X, Liu K, Zhang JH, et al. Repetitive hyperbaric oxygen exposures enhance sensitivity to convulsion by upregulation of eNOS and nNOS. *Brain Res.* 2008; 1201:128–134.
76. Lynch JW. Molecular structure and function of the glycine receptor chloride channel. *Physiol Rev.* 2004; 84(4):1051–1095.
77. Mayevsky A, Shaya B. Factors affecting the development of hyperbaric oxygen toxicity in the awake rat brain. *J Appl Physiol.* 1980; 49(4): 700–707.
78. Mendzheritskii AM, Lysenko AV, Uskova NI, Sametskii EA. [The mechanism of the anticonvulsive effect of the delta sleep-inducing peptide under conditions of elevated oxygen pressure]. [Article in Russian, Abstract in English]. *Fiziol Zh Im I M Sechenova.* 1996; 82(1):59–64.
79. Medicare definition and indications for hyperbaric oxygen therapy [Internet]. c2015 [cited 2015 Nov 11]. Available from: <https://www.medicare.gov/coverage/hyperbaric-oxygen-therapy.html>.
80. Mialon P, Gibey R, Bigot JC, Barthelemy L. Changes in striatal and cortical amino acid and ammonia levels of rat brain after one hyperbaric oxygen-induced seizure. *Aviat Space Environ Med.* 1992; 63(4): 287–291.
81. Mialon P, Joanny P, Gibey R, Cann-Moisson C, Caroff J, et al. Amino acids and ammonia in the cerebral cortex, the corpus striatum and the brain stem of the mouse prior to the onset and after a seizure induced by hyperbaric oxygen. *Brain Res.* 1995; 676(2):352–357.
82. Moskvina AN, Zhilyaev SY, Sharapov OI, Platonova TF, Gutsaeva DR, et al. Brain blood flow modulates the neurotoxic action of hyperbaric oxygen via neuronal and endothelial nitric oxide. *Neurosci Behav Physiol.* 2003; 33(9):883–888.

83. Naval Sea Systems Command, United States Department of the Navy. Navy diving manual, 5th ed. Washington (DC): U.S. Government Printing Office; 2005.
84. National Coverage Determination (NCD) for Hyperbaric Oxygen Therapy. (20.29), Centers for Medicare and Medicaid Services [Internet]. c2015 [cited 2015 Dec 12]. Available from: [www.cms.gov](http://www.cms.gov).
85. Nelson LS, Lewin NA, Howland MA, Hoffman RS, Goldfrank LR, Flomenbaum NE. Goldfrank's toxicologic emergencies, 9th ed. New York (NY): McGraw Hill; 2011.
86. National Institutes of Health, National Library of Medicine [Internet]. C2015 [cited 2015 Dec 1]. Available from: [clinicaltrials.gov](http://clinicaltrials.gov).
87. Olivero M. Hospitals Tout Benefits of Hyperbaric Oxygen Therapy [Internet]. 6 Oct 2014 [cited 2015 Nov 11]. Available from: <http://www.usnews.com/news/articles/2014/10/06/hospitals-tout-benefits-of-hyperbaric-oxygen-therapy>.
88. Oury TD, Ho YS, Piantadosi CA, Crapo JD. Extracellular superoxide dismutase, nitric oxide, and central nervous system O<sub>2</sub> toxicity. *Proc Natl Acad Sci USA*. 1992; 89(20):9715–9719.
89. Pace N, Strajman E, Walker EL. Acceleration of carbon monoxide elimination in man by high pressure oxygen. *Science*. 1950; 111(2894): 652–654.
90. Piantadosi CA, Tatro LG. Regional H<sub>2</sub>O<sub>2</sub> concentration in rat brain after hyperoxic convulsions. *J Appl Physiol*. 1990 Nov 69(5):1761–1766.
91. Pilla R, Held HE, Landon CS, Dean JB. High doses of pseudoephedrine hydrochloride accelerate onset of CNS oxygen toxicity seizures in unanesthetized rats. *Neuroscience*. 2013; 246:391–396.
92. Plafki C, Peters P, Almeling M, Welslau W, Busch R. Complications and side effects of hyperbaric oxygen therapy. *Aviat Space Environ Med*. 2000; 71(2):119–124.
93. Puglia CD, Loeb GA. Influence of rat brain superoxide dismutase inhibition by diethyldithiocarbamate upon the rate of development of central nervous system oxygen toxicity. *Toxicol Appl Pharmacol*. 1984; 75(2):258–264.
94. Raman G, Kupelnick B, Chew P, Lau J. A Horizon Scan: Uses of Hyperbaric Oxygen Therapy [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2006 Oct 05. Available from <http://www.ncbi.nlm.nih.gov/books/NBK299143/>.
95. Reshef A, Bitterman N, Kerem D. The effect of carbamazepine and ethosuximide on hyperoxic seizures. *Epilepsy Res*. 1991; 8(2):117–121.
96. Roche CJ, Dantsker D, Samuni U, Friedman JM. Nitrite reductase activity of sol-gel-encapsulated deoxyhemoglobin. Influence of quaternary and tertiary structure. *J Biol Chem*. 2006; 281(48):36874–36882 Epub 2006 Sep 19.
97. Sanders RW, Katz KD, Suyama J, Akhtar J, O'Toole KS, et al. Seizure during hyperbaric oxygen therapy for carbon monoxide toxicity: a case series and five-year experience. *J Emerg Med*. 2012; 42(4):e69–72.
98. Sato T, Takeda Y, Hagioka S, Zhang S, Hirakawa M. Changes in nitric oxide production and cerebral blood flow before development of hyperbaric oxygen-induced seizures in rats. *Brain Res*. 2001; 918(1-2):131–140.
99. Seckin M, Gurgor N, Beckmann YY, Ulukok MD, Suzen A, Basoglu M. Focal status epilepticus induced by hyperbaric oxygen therapy. *Neurologist*. 2011; 17(1):31–33.
100. Seidel R, Carroll C, Thompson D, Diem RG, Yeboah K, et al. Risk factors for oxygen toxicity seizures in hyperbaric oxygen therapy: case reports from multiple institutions. *Undersea Hyperb Med*. 2013; 40(6):515–519.
101. Shelton CJ, Doyle MG, Price DJ, Daniels S, Smith EB. The effect of high pressure on glycine- and kainate-sensitive receptor channels expressed in *Xenopus* oocytes. *Proc Biol Sci*. 1993; 254(1340):131–137.
102. Shykoff B. Incidence of CNS oxygen toxicity with mild hyperoxia: a literature and data review. Panama City (FL): Navy Experimental Dive Unit; 2013; TA 12-03 NEDU TR 13-03.
103. Singh AK, Banister EW. Relative effects of hyperbaric oxygen on cations and catecholamine metabolism in rats: protection by lithium against seizures. *Toxicology*. 1981; 22(2):133–147.
104. Thom SR. Hyperbaric oxygen – its mechanisms and efficacy. *Plast Reconstr Surg*. 2011; 127(Suppl 1):131S–141S.
105. Thom SR. Oxidative stress is fundamental to hyperbaric oxygen therapy. *J Appl Physiol* (1985). 2009; 106(3):988–995.
106. Thomson L, Paton J. Oxygen toxicity. *Paediatr Respir Rev*. 2014; 15(2): 120–123.
107. Tibbles PM, Edelsberg JS. Hyperbaric-oxygen therapy. *N Engl J Med*. 1996;334(25):1642–1648.
108. Torbati D, Church DF, Keller JM, Pryor WA. Free radical generation in the brain precedes hyperbaric oxygen-induced convulsions. *Free Radic Biol Med*. 1992; 13(2):101–106.
109. Torbati D, Lambertsen CJ. Regional cerebral metabolic rate for glucose during hyperbaric oxygen-induced convulsion. *Brain Res*. 1983; 279(1-2): 382–386.
110. Tzuk-Shina T, Bitterman N, Harel D. The effect of vigabatrin on central nervous system oxygen toxicity in rats. *Eur J Pharmacol*. 1991; 202(2):171–175.
111. Vion-Dury J, LeGal La Salle G, Rougier I, Papy JJ. Effects of hyperbaric and hyperoxic conditions on amygdala-kindled seizures in rat. *Exp Neurol*. 1986; 92(3):513–521.
112. Voronov IB. Brain structures and origin of convulsions caused by high oxygen pressure (HOP). *Int J Neuropharmacol*. 1964; 3:279–282.
113. Walker J. Hyperbaric oxygen therapy gets more popular as unapproved treatment: use of HBOT to treat autism, brain injury is growing despite a lack of conclusive evidence [Internet]. *Wall Street Journal*; 5 Jan 2015 [cited 2015 Nov 11]. Available from: <http://www.wsj.com/articles/hyperbaric-oxygen-therapy-gets-more-popular-as-unapproved-autism-treatment-1420496506>.
114. Walter FG, Chase PB, Fernandez MC, Cameron D, Roe DJ, Wolfson M. Pyridoxine does not prevent hyperbaric oxygen-induced seizures in rats. *J Emerg Med*. 2006; 31(2):135–138.
115. Wang WJ, Ho XP, Yan YL, Yan TH, Li CL. Intrasyaptosomal free calcium and nitric oxide metabolism in central nervous system oxygen toxicity. *Aviat Space Environ Med*. 1998; 69(6):551–555.
116. Weaver LK. Phenytoin sodium in oxygen-toxicity-induced seizures. *Ann Emerg Med*. 1983; 12(1):38–41.
117. Whelan HT, Bajic DM, Karlovits SM, Houle JM, Kindwall EP. Use of cytochrome-P450 mono-oxygenase 2 E1 isozyme inhibitors to delay seizures caused by central nervous system oxygen toxicity. *Aviat Space Environ Med*. 1998; 69(5):480–485.
118. Witucki P, Duchnick J, Neuman T, Grover I. Incidence of DCS and oxygen toxicity in chamber attendants: a 28-year experience. *Undersea Hyperb Med*. 2013; 40:345–350.
119. Wood CD. Acetazolamide and CO<sub>2</sub> in hyperbaric oxygen toxicity. *Undersea Biomed Res*. 1982; 9(1):15–20.
120. Wood JD. The role of gamma-aminobutyric acid in the mechanism of seizures. *Prog Neurobiol*. 1975; 5(1):77–95.
121. Wood JD, Watson WJ, Murray GW. Correlation between decreases in brain gamma-aminobutyric acid levels and susceptibility to convulsions induced by hyperbaric oxygen. *J Neurochem*. 1969; 16(3):281–287.
122. Wylie DC, Das J, Chakraborty AK. Sensitivity of T cells to antigen and antagonism emerges from differential regulation of the same molecular signaling module. *Proc Natl Acad Sci USA*. 2007; 104(13): 5533–5538.
123. Xiao X, Wang ZZ, Xu WG, Xiao K, Cai ZY, et al. Cerebral blood flow increase during prolonged hyperbaric oxygen exposure may not be necessary for subsequent convulsion. *CNS Neurosci Ther*. 2012; 18(11):947–949.
124. Yildiz S, Aktas S, Cimsit M, Ay H, Toğrol E. Seizure incidence in 80,000 patient treatments with hyperbaric oxygen. *Aviat Space Environ Med*. 2004; 75:992–994.
125. Yoles E, Zurovsky Y, Zarchin N, Mayevsky A. The effect of hyperbaric hyperoxia on brain function in the newborn dog in vivo. *Neurol Res*. 2000; 22(4):404–408.
126. Zhang C, Bélanger S, Pouliot P, Lesage F. Measurement of local partial pressure of oxygen in the brain tissue under normoxia and epilepsy with phosphorescence lifetime microscopy. *PLoS ONE*. 2015;10(8): e0135536.